BioLineRx Ltd.
BLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.84 | -0.70 | 2.32 | 2.02 |
| FCF Yield | -6.42% | -0.57% | -2.18% | -0.66% |
| EV / EBITDA | 175.68 | -70.78 | -42.78 | -149.46 |
| Quality | ||||
| ROIC | -71.60% | -200.27% | -43.08% | -33.21% |
| Gross Margin | 67.99% | 23.08% | 0.00% | 0.00% |
| Cash Conversion Ratio | 4.76 | 0.37 | 1.05 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -91.78% | 13.75% | -12.19% | -2.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.18 | -0.13 | -0.06 | 0.35 |
| Interest Coverage | -2.23 | -22.91 | -13.51 | -25.18 |
| Efficiency | ||||
| Inventory Turnover | 2.95 | 1.89 | 0.00 | 0.00 |
| Cash Conversion Cycle | -47.35 | -827.62 | 0.00 | 0.00 |